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331 First trimester prediction of uteroplacental
disease- results of the prospective handle study
Cathy Monteith1, Lisa McSweeney1, Colm R. Breathnach1,
Lucy Shirren1, Patrick Dicker1, Elizabeth C. Tully1,
John O’Loughlin2, Sharon Campbell2, Greg Byrne3,
Fergal D. Malone1, Afif EL-Khuffash2, Etaoin Kent2, Ann Doherty2
1RCSI, Dublin, Ireland, 2Rotunda Hospital, Dublin, Ireland, 3Dublin Institute
of Technology, Dublin, Ireland
OBJECTIVE: To assess the ability of non-invasive cardiac output
monitoring (NICOM), a novel method of non-invasive maternal
hemodynamic assessment using bioreactance, in combination with
first trimester biomarkers to predict the evolution of gestational
hypertension (GH), pre-eclampsia (PE) and normotensive fetal
growth restriction (FGR).
STUDY DESIGN: Low risk nulliparous women were enrolled in a single
center prospective observational study. NICOM assessments were
performed at 14 weeks’ gestation and data obtained on cardiac
output (CO), indexed CO (adjusted for maternal body surface area;
COI), total peripheral resistance (TPR), indexed TPR (adjusted for
maternal body surface area; TPRi), stroke volume (SV), indexed SV
(adjusted for maternal body surface area; SVi) and heart rate (HR).
Maternal serum samples were obtained in the first trimester and the
following markers were analysed: placental growth factor (PLGF;
Cobas Roche); soluble fms-like tyrosine-1 (s-flt-1; Elecsys) Apelin
13 (Nori ELISA) and mean platelet volume (MPV). Corrleation
between cardiac variables and biomarkers was assessed using
Spearman coefficient. Discriminant analysis was employed to model
GH, PE and FGR with NICOM and biomarker measurements as
predictors. Logistic regression was performed on variables of interest
via SAS version 9.0.
RESULTS: The haemodynamic profile of pregnancies complicated by
uteroplacental disease- GH (n¼13), PE (n¼5) and FGR (n¼18)
were compared to 61 healthy unaffected pregnant controls.Apelin 13
demonstrated a negative correlation with TPRi (r¼-0.29, p¼0.004),
and a positive correlation with COi (r¼0.29, p¼0.005). In the pre-
diction of PE s-flt-1 and MPV had a combined prediction model
AUC 0.88 (p¼0.01). Whereas in the prediction of FGR s-flt-1, SV
and TPRI had a combined prediction model AUC 0.76 (p¼0.007).
CONCLUSION: Apelin 13 is an inodilator produced by the normal
placenta in pregnancy. This study shows the hemodynamic effects of
Apelin 13 are present as early as 14 weeks’ gestation. Down regu-
lation of placental Apelin 13 has been linked with PE and lower
serum Apelin with FGR, from 20 weeks’ gestation onwards. How-
ever, this association was not present at 14 weeks’ gestation. In
addition to its known use in PE, first trimester s-flt-1 may have an
role in the prediction of FGR which is strengthened by the addition
of hemodynamic variables.
332 Can a point-of-care hemoglobin device replace
complete blood count for fetal blood sampling
during intrauterine transfusion?
Cathy Monteith1, Jahan Jadauji1, Hala Abu1, Ann M. McHugh1,
Jennifer C. Donnelly2, Ciaran Mooney2, Siobhan Enright2,
Niamh Hayes2, Fergal D. Malone1
1RCSI, Dublin, Ireland, 2Rotunda Hospital, Dublin, Ireland
OBJECTIVE: Our objective was to prospectively validate a Point-of-
Care (POC) hemoglobin device (Hemocue 201 DM system) as an
alternative to a laboratory based complete blood count (CBC) in the
setting of hemoglobin evaluation during cordocentesis and intra-
uterine fetal transfusion.
STUDY DESIGN: This prospective study was performed in a tertiary
level maternity hospital. Fifteen consecutive cases of fetal anemia
attending the hospital for cordocentesis and intrauterine fetal
transfusion over an 18 month period were included. At the time of
cordocentesis all participants had at least two episodes of dual fetal
blood sampling with both a POC Test and a laboratory-based CBC.
Statistical analysis was performed via Pearson’s test.
RESULTS: Fifteen cordocentesis procedures were performed during
the 18 month period yielding a total of 35 paired samples. There was
strong correlation between the POC hemoglobin and a CBC he-
moglobin with r¼0.976 (95% CI 0.952-0.988) and a p value
<0.0001. This study demonstrated a linear fit between both methods
of hemoglobin quantification enabling the prediction of the antici-
pated CBC hemoglobin from CBC hemoglobin via the equation
Hemocue Hemoglobin ¼ 2.902 + 0.9617 Laboratory Hemoglobin.
CONCLUSION: Overall there is good agreement between the POC fetal
hemoglobin and the CBC fetal hemoglobin. This suggests that the
Hemocue 201 DM system is a viable and reproducible alternative
form of measurement of fetal hemoglobin, with the important
advantage of providing expedited results at the bedside. This ulti-
mately may reduce fetal morbidity associated with cordocentesis and
intrauterine transfusion, minimizing the time required to complete
the procedure.
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333 Potential preeclampsia therapy tested
Asif Ahmed, Keqing Wang, Shakil Ahmad, Homira Rezai
Aston Medical School of Aston University, Birmingham,
United Kingdom
OBJECTIVE: Low circulating levels of placenta growth factor (PlGF) is
strongly associated with the onset of preeclampsia. Although, PlGF-
deficient mice are born healthy and fertile at a Mendelian ratio, the
physiological importance of PlGF in the pathogenesis of pre-
eclampsia is unclear. We hypothesised that decreased levels of PlGF
in pregnancy exacerbates the fetal growth restriction associated with
preeclampsia in the presence of high soluble Flt-1 (sFlt-1). Earlier
studies showed that heme oxygenase-1 (HO-1) pathway inhibits
sFlt-1 and as hydrogen sulfide (H2S) stimulates HO-1, we argued
H2S donors will recuse the defects.
STUDY DESIGN: Pregnant PlGF-/- mice were injected with adenovirus
encoding sFlt-1 (Ad-sFlt-1) at high (i) 1.5x109 pfu/ml and low (ii)
0.5x109 pfu/ml doses. Mean arterial blood pressure (MBP),
biochemical and histological assessments of maternal kidney,
placenta and embryos were performed.
RESULTS: Ad-sFlt-1 significantly increased MBP and induced se-
vere glomerular endotheliosis in PlGF-/- mice at E10.5 gestation
compared to wild-type animals. High sFlt-1 also significantly
elevated albumin-creatinine ratio and increased levels of urinary
kidney injury molecule-1, a marker for proximal tubule injury. At
a high dose of sFlt-1, there was complete fetal resorption in the
pregnant PlGF-/- mice, and even the lower dose of sFlt-1 induced
severe fetal resorption and abnormal placental vascularization.
H2S-releasing agent, GYY4137, significantly reduced resorption,
hypertension and proteinuria in Ad-sFlt-1 treated pregnant
PlGF-/- mice. To determine if placental PlGF is critical for pre-
venting fetal growth restriction associated with preeclampsia, we
generated haploinsufficient PlGF+/- placentas and embryos were
generated in wild-time dams and exposed to high sFlt-1 envi-
ronment. This resulted in reduced fetal resorption, gestational
hypertension and proteinuria when compared to pregnant PlGF-/-
mice.
CONCLUSION: Placental PlGF is a critical protective factor against
the damaging effects of high sFlt-1 associated with preeclampsia
and activation of the H2S pathway appears to rescue pre-
eclampsia phenotype even under low PlGF environment possibly
by upregulating other protective pathways such as the HO-1/CO
system.
334 Preeclampsia with severe features: Is
Ibuprofen dose associated with elevated blood
pressures postpartum?
Jonathan S. Hirshberg, Shahroz Fatima, Julia D. Lo´pez,
Methodius G. Tuuli, George A. Macones, Alison G. Cahill
Washington University School of Medicine in St. Louis, St. Louis, MO
OBJECTIVE: The American College of Obstetricians and Gynecolo-
gists (ACOG) Task Force statement on Hypertension in Pregnancy
recommends that clinicians withhold nonsteroidal anti-inflamma-
tory medications in patients with postpartum hypertension. We
sought to determine if there was a dose dependent association be-
tween Ibuprofen dose and blood pressures postpartum in those with
preeclampsia with severe features.
STUDY DESIGN: This was a planned secondary analysis of a pro-
spective cohort study of consecutive term patients meeting diag-
nostic criteria for preeclampsia with severe features delivered at a
single academic medical center. Ibuprofen dose, frequency and time
of administration were collected during the postpartum course.
Noninvasive measurements of systolic and diastolic blood pressures
(NIBP) were used to calculate daily mean arterial pressure (MAP).
Association between Ibuprofen dose and MAPs were estimated using
parametric T-tests.
RESULTS: Of the 335 patients in our analysis, 94% received Ibuprofen
postpartum. For those that received Ibuprofen, there was no asso-
ciation between daily Ibuprofen dose and mean postpartum MAP
(Figure). The median total dose of ibuprofen was 3g during the
postpartum hospitalization. Patients who received more than 3g of
ibuprofen had an average MAP of 100.59.1 mmHg, which did not
differ significantly from those who received less than 3g (99.49.4
mmHg, p¼ 0.28). This relationship persisted across modes of de-
livery (Table).
CONCLUSION: There is no association between postpartum ibuprofen
use with standard dosing and mean arterial blood pressure in pa-
tients with preeclampsia with severe features.
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